{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:46:02Z","timestamp":1770777962286,"version":"3.50.0"},"reference-count":44,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Large volume delayed sampling (LVDS) and pathogen reduction technology (PRT) are strategies for platelet processing to minimize transfusion of contaminated platelet components (PCs). This study holistically compares the economic and clinical impact of LVDS and PRT in the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design and Methods<\/jats:title><jats:p>A decision model was constructed to simulate collection, processing, and use of PCs and to compare processing strategies: PRT with 5\u2010day shelf life, LVDS with 7\u2010day shelf life (LVDS7), and LVDS with 5\u2010day shelf life extended to 7\u2009days with secondary testing (LVDS5\/2). Target population was adults requiring two or more transfusions. Collection, processing, storage, and distribution data were obtained from the National Blood Collection and Utilization Survey and published literature. Patient outcomes associated with transfusions were obtained from AABB guidelines, meta\u2010analyses, and other published clinical studies. Costs were obtained from reimbursement schedules and other published sources.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Given 10,000 donated units, 9512, 9511, and 9651\u2009units of PRT, LVDS5\/2, and LVDS7 PCs were available for transfusion, respectively. With these units, 1502, 2172, and 2329 transfusions can be performed with similar levels of adverse events. Assuming 30 transfusions a day, a hospital would require 69,325, 47,940, and 45,383\u2009units of PRT, LVDS5\/2, and LVDS7 platelets to perform these transfusions. The mean costs to perform transfusions were significantly higher with PRT units.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compared with PRT, LVDS strategies were associated with lower costs and higher PC availability while patients experienced similar levels of adverse events. Increased utilization of LVDS has the potential to improve efficiency, expand patient access to platelets, and reduce health care costs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.16589","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T20:30:25Z","timestamp":1626899425000},"page":"2885-2897","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-6509","authenticated-orcid":false,"given":"Stephanie","family":"Earnshaw","sequence":"first","affiliation":[{"name":"Health Economics RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Beyhaghi","sequence":"additional","affiliation":[{"name":"Medical Affairs Novavax Inc  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"McDade","sequence":"additional","affiliation":[{"name":"Health Economics RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Purser","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes GlaxoSmithKline LLC  Upper Providence Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Marriott","sequence":"additional","affiliation":[{"name":"Laboratory Operations Consulting Marriott Quality and Performance Solutions LLC  Raleigh NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Daane","sequence":"additional","affiliation":[{"name":"Industry Healthcare Division bioM\u00e9rieux, Inc.  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Le Coent","sequence":"additional","affiliation":[{"name":"Industry Healthcare Division bioM\u00e9rieux SA  Craponne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Yang","sequence":"additional","affiliation":[{"name":"Industry Healthcare Division bioM\u00e9rieux, Inc.  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Toback","sequence":"additional","affiliation":[{"name":"Medical Affairs Novavax Inc  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"FDA.Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. Guidance for industry. Food and Drug Administration (FDA). 2020.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/bacterial\u2010risk\u2010control\u2010strategies\u2010blood\u2010collection\u2010establishments\u2010and\u2010transfusion\u2010services\u2010enhance. Accessed 26 Jan 2021."},{"issue":"1","key":"e_1_2_7_3_1","first-page":"5","article-title":"Improving the safety of platelets by increasing the sample volume and time for sampling and issuing \u2013 bacteriological results","volume":"113","author":"Bernier F","year":"2018","journal-title":"Vox Sang"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14085"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/aob-21-4"},{"key":"e_1_2_7_6_1","first-page":"40","article-title":"A review of testing strategies for bacterial risk control in platelets recommended by the FDA","volume":"2","author":"Vallejo RP","year":"2021","journal-title":"J Clin Haematol"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12085"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164137"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08635.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08227.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01555.x"},{"key":"e_1_2_7_12_1","unstructured":"BacT\/ALERT\u00ae.BacT\/ALERT\u00ae BPN package insert. bioM\u00e9rieux Inc.2020.https:\/\/www.fda.gov\/media\/138272\/download. Accessed 14 July 2020."},{"key":"e_1_2_7_13_1","unstructured":"INTERCEPT\u00ae.INTERCEPT\u00ae blood system for platelets \u2013large volume (LV) processing set package insert. Cerus Corporation.2016.https:\/\/www.fda.gov\/media\/90089\/download. Accessed 14 July 2020."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16001"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15762"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14165"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13149"},{"key":"e_1_2_7_18_1","unstructured":"SorkinE JacobsonJ.Predicted costs of implementing PGD testing and pathogen reduction in a hospital transfusion service. Presented at the AABB Annual Meeting; October 22\u201325 2016 Orlando FL."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00550.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4443"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14042"},{"key":"e_1_2_7_22_1","first-page":"CD009072\u2010CD","article-title":"Pathogen\u2010reduced platelets for the prevention of bleeding","volume":"7","author":"Estcourt LJ","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000000794"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.1734"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0932"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1589"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-655944"},{"key":"e_1_2_7_28_1","unstructured":"CMS.Hospital Outpatient Prospective Payment System (OPPS). Centers for Medicare & Medicaid Services.2020.https:\/\/www.cms.gov\/Medicare\/Medicare\u2010Fee\u2010for\u2010Service\u2010Payment\/HospitalOutpatientPPS\/Addendum\u2010A\u2010and\u2010Addendum\u2010B\u2010Updates. Accessed 4 Apr 2020."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14216"},{"key":"e_1_2_7_30_1","unstructured":"US BEA.US Bureau of Economic Analyses (BEA). Table 2.4.4U. Price indexes for personal consumption expenditures by type of product.2020.https:\/\/apps.bea.gov\/iTable\/iTable.cfm?ReqID=19&step=2#reqid=19&step=2&isuri=1&1921=underlying. Accessed 1 Apr 2020."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530740-000000000-00000"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-018-0409-3"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anclin.2010.11.007"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642560"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12386"},{"key":"e_1_2_7_36_1","unstructured":"CMS.Physician fee schedule. Centers for Medicare & Medicaid Services.2020.https:\/\/www.cms.gov\/apps\/physician-fee-schedule. Accessed 4 Apr 2020."},{"key":"e_1_2_7_37_1","unstructured":"HCUPnet.Healthcare cost and utilization project. Agency for Healthcare Research and Quality.2020.https:\/\/hcupnet.ahrq.gov\/. Accessed 2 April 2020."},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14198"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02236.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15139"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15773"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16112"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14305"},{"key":"e_1_2_7_44_1","unstructured":"NguyenH BenjaminR PizziL AndrewsJ.Pathogen reduction of platelets: hospital perspectives on economic efficiencies pediatric patient safety and implementation.2020.https:\/\/www.gotostage.com\/channel\/ed6681982a004becb102657532d9ceb3\/recording\/9235c57f4b694ded9b4864d0dd83fce8\/watch\/7244443932451687440?source=REGISTER. Accessed 26 Jan 2021."},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13038"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16589","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:47:48Z","timestamp":1693342068000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/trf.16589"],"URL":"https:\/\/doi.org\/10.1111\/trf.16589","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"2021-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}